Cargando…
High Serum CEA and CYFRA21-1 Levels after a Two-Cycle Adjuvant Chemotherapy for NSCLC: Possible Poor Prognostic Factors
OBJECTIVE: The aim of this study was to test whether carcinoembryonic antigen (CEA) and cytokeratin 19 fragments (CYFRA21-1) can be used as a prognostic factor for non-small-cell lung cancer (NSCLC) after two cycles of adjuvant chemotherapy in NSCLC patients. METHODS: A total of 169 patients underwe...
Autores principales: | Lin, Xue-feng, Wang, Xiao-dong, Sun, Da-qiang, Li, Zhi, Bai, Yue |
---|---|
Formato: | Online Artículo Texto |
Lenguaje: | English |
Publicado: |
Chinese Anti-Cancer Association
2012
|
Materias: | |
Acceso en línea: | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC3643679/ https://www.ncbi.nlm.nih.gov/pubmed/23691489 http://dx.doi.org/10.7497/j.issn.2095-3941.2012.04.009 |
Ejemplares similares
-
Prognostic value of serum CYFRA21-1 and CEA for non-small-cell lung cancer
por: Zhang, Zhi-Hui, et al.
Publicado: (2015) -
CEA and CYFRA 21-1 as prognostic biomarker and as a tool for treatment monitoring in advanced NSCLC treated with immune checkpoint inhibitors
por: Dall’Olio, Filippo G., et al.
Publicado: (2020) -
Postoperative CYFRA 21-1 and CEA as prognostic factors in patients with stage I pulmonary adenocarcinoma
por: He, Ying, et al.
Publicado: (2017) -
The Role of Change Rates of CYFRA21-1 and CEA in Predicting Chemotherapy Efficacy for Non-Small-Cell Lung Cancer
por: Zhao, Tongwei, et al.
Publicado: (2021) -
The role of CEA, CYFRA21-1 and NSE in monitoring tumor response to Nivolumab in advanced non-small cell lung cancer (NSCLC) patients
por: Dal Bello, M. G., et al.
Publicado: (2019)